Search
                    Oregon Paid Clinical Trials
A listing of 1212  clinical trials  in Oregon  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1021 - 1032 of 1212
        
                Oregon is currently home to 1212 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Mucopolysaccharidosis I (MPS I) Registry
                                
            
            
        Recruiting
                            
            
                The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the lon...  Read More             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                11/19/2024
            
            Locations: Oregon Health and Science University- Site Number : 840080, Portland, Oregon         
        
        
            Conditions: Mucopolysaccharidosis I (MPS I)
        
            
        
    
                
                                    A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
                                
            
            
        Recruiting
                            
            
                Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surg...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/18/2024
            
            Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon         
        
        
            Conditions: Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
        
            
        
    
                
                                    Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
                                
            
            
        Recruiting
                            
            
                This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.
It also contains a sub-study to enroll patients with severe COVID-19.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                11/18/2024
            
            Locations: Oregon Health & Science University, Portland, Oregon         
        
        
            Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
        
            
        
    
                
                                    Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
                                
            
            
        Recruiting
                            
            
                Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 55 years and 90 years
            Trial Updated:
                11/18/2024
            
            Locations: Oregon Health & Science University, Portland, Oregon         
        
        
            Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
        
            
        
    
                
                                    Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep to Reward- and Stress-Related Brain Function
                                
            
            
        Recruiting
                            
            
                This research will use biobehavioral approaches to generate understanding about the linkages between sleep duration and timing, stressful life events, and depressive symptoms in adolescents, with a long-term aim of developing effective preventative interventions.             
        
        
    Gender:
                ALL
            Ages:
                Between 14 years and 18 years
            Trial Updated:
                11/15/2024
            
            Locations: University of Oregon, Eugene, Oregon         
        
        
            Conditions: Depression in Adolescence
        
            
        
    
                
                                    Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
                                
            
            
        Recruiting
                            
            
                This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/14/2024
            
            Locations: Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon         
        
        
            Conditions: Refractory Differentiated Thyroid Gland Carcinoma
        
            
        
    
                
                                    Study of Enhanced Programming Stimulation with the Enterra® Therapy System
                                
            
            
        Recruiting
                            
            
                The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life measures.
Participants in this study will be evaluated for study entry criteria, have an Enterra Therapy System implanted, and be randomly assigned to one of two programming strategies. Participants will answer daily questions about their gastroparesis symptoms on an appl...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                11/13/2024
            
            Locations: Foundation for Surgical Innovation, Portland, Oregon         
        
        
            Conditions: Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
        
            
        
    
                
                                    Evaluation of Gixam's Performance in a FIT Negative Population
                                
            
            
        Recruiting
                            
            
                In the United States, colorectal cancer ranks second to lung cancer as a cause of cancer death and is the third most commonly occurring cancer in both men and women. Colorectal cancer in most cases develops slowly over a period of years, starting with the growth of precancerous polyps on the colon or rectum wall. The slow development of colorectal cancer makes it possible to detect and prevent it entirely by the removal of the precancerous polyps with colonoscopy. To date, there is no screening...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 45 years and 85 years
            Trial Updated:
                11/12/2024
            
            Locations: The Oregon Clinic Gastroenterology-East, Portland, Oregon         
        
        
            Conditions: Colorectal Adenoma, Colorectal Cancer (CRC), Colorectal Cancer (CRC) Screening
        
            
        
    
                
                                    Study in Parkinson Disease of Exercise
                                
            
            
        Recruiting
                            
            
                This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 80 years
            Trial Updated:
                11/12/2024
            
            Locations: Oregon Health & Science University, Portland, Oregon         
        
        
            Conditions: Parkinson Disease
        
            
        
    
                
                                    Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
                                
            
            
        Recruiting
                            
            
                To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.             
        
        
    Gender:
                ALL
            Ages:
                Between 12 years and 45 years
            Trial Updated:
                11/09/2024
            
            Locations: Pacific Clear Vision Institute, Eugene, Oregon         
        
        
            Conditions: Keratoconus, Unstable, Bacterial Keratitis, Ectasia of Cornea
        
            
        
    
                
                                    The Use of Voice-Based AI in 988 Crisis Counseling
                                
            
            
        Recruiting
                            
            
                Effective training requires repeated opportunities for skills practice with performance-based feedback, which is challenging to provide at scale. This research study focuses on developing an AI-based, coding and feedback tool ("LyssnCrisis") for implementation in a nationally utilized crisis call center, training counselors (call-takers) in suicide risk assessment skills, and evaluating LyssnCrisis to improve services and client outcomes. This research study's goal is to maximize the human capac...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/08/2024
            
            Locations: ProtoCall Services, Inc., Portland, Oregon         
        
        
            Conditions: Suicide, Suicide and Self-harm
        
            
        
    
                
                                    Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
                                
            
            
        Recruiting
                            
            
                This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/08/2024
            
            Locations: Oregon Health and Science University, Portland, Oregon         
        
        
            Conditions: Myelodysplastic Syndromes
        
            
        
    